[go: up one dir, main page]

AR054347A1 - Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion - Google Patents

Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion

Info

Publication number
AR054347A1
AR054347A1 ARP060101594A ARP060101594A AR054347A1 AR 054347 A1 AR054347 A1 AR 054347A1 AR P060101594 A ARP060101594 A AR P060101594A AR P060101594 A ARP060101594 A AR P060101594A AR 054347 A1 AR054347 A1 AR 054347A1
Authority
AR
Argentina
Prior art keywords
depression
treatment
prevention
therapeutic combinations
combinations
Prior art date
Application number
ARP060101594A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36809594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054347(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR054347A1 publication Critical patent/AR054347A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan combinaciones terapéuticas utiles en el tratamiento o prevencion de la depresion u otros trastornos del temperamento, composiciones farmacéuticas que contienen dichas combinaciones, y su uso en el tratamiento o profilaxis de la depresion u otros trastornos del temperamento. Tales compuestos son de formula (1), o una sal farmacéuticamente aceptable de los mismos, donde cada uno de R1, R2, R3, n, y, y Ar son como de definio y describio en la presente.
ARP060101594A 2005-04-22 2006-04-21 Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion AR054347A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67404805P 2005-04-22 2005-04-22

Publications (1)

Publication Number Publication Date
AR054347A1 true AR054347A1 (es) 2007-06-20

Family

ID=36809594

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101594A AR054347A1 (es) 2005-04-22 2006-04-21 Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion

Country Status (13)

Country Link
US (2) US7396857B2 (es)
EP (1) EP1871355A1 (es)
JP (1) JP2008536946A (es)
CN (1) CN101198322A (es)
AR (1) AR054347A1 (es)
AU (1) AU2006239918A1 (es)
BR (1) BRPI0610044A2 (es)
CA (1) CA2604915A1 (es)
GT (1) GT200600163A (es)
MX (1) MX2007012882A (es)
PE (1) PE20061327A1 (es)
TW (1) TW200722081A (es)
WO (1) WO2006116149A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
RU2007139543A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные бензодиоксана и бензодиоксолана и их применение
MX2007013023A (es) * 2005-04-22 2007-12-13 Wyeth Corp Tratamiento del dolor.
GT200600166A (es) * 2005-04-22 2007-03-14 Derivados de cromano y cromeno y usos de los mismos
MX2007012936A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
CA2605435A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AR056321A1 (es) * 2005-04-22 2007-10-03 Wyeth Corp COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
EP1871755A1 (en) * 2005-04-22 2008-01-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AU2006239922A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
EP1874292A2 (en) * 2005-04-24 2008-01-09 Wyeth Methods for modulating bladder function
MX2008012212A (es) * 2006-03-24 2008-10-02 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines.
AU2008248382B2 (en) * 2007-05-07 2013-07-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
CN102250048B (zh) * 2011-06-03 2013-06-05 浙江工业大学 2-苯硒基甲基-2,3-二氢苯并呋喃及其制备与应用
JP6709887B2 (ja) * 2014-09-26 2020-06-17 ヒューマン・メタボローム・テクノロジーズ株式会社 うつ病治療薬の選択肢を予測する方法
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2020168337A1 (en) 2019-02-17 2020-08-20 Magid Abraham Compositions and methods for treatment of depression and other disorders
CN120040398A (zh) 2020-06-08 2025-05-27 泰科根公司 用于精神障碍或精神增强的有利苯并呋喃组合物
CA3187217A1 (en) 2020-08-06 2022-02-10 Matthew BAGGOTT 2-aminoindane compounds for mental disorders or enhancement

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3513239A (en) * 1967-03-15 1970-05-19 Smithkline Corp Pharmaceutical compositions containing 2-aminoalkyl coumaran derivatives and methods of treating depression therewith
US3826835A (en) * 1971-01-08 1974-07-30 Ciba Geigy Corp 8-benzofurylmethyl-1,3,8-triazaspiro(4,5)decanes as neuroleptics
JPS59186969A (ja) * 1983-04-08 1984-10-23 Yoshitomi Pharmaceut Ind Ltd ベンゾフラン−およびベンゾピランカルボキサミド誘導体
JPH06316563A (ja) 1993-05-06 1994-11-15 Yoshitomi Pharmaceut Ind Ltd アミド化合物
ES2273764T3 (es) * 1993-06-28 2007-05-16 Wyeth Nuevos tratamientos que utilizan derivados de fenetilamina.
US6150402A (en) * 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
AU1106195A (en) 1994-11-09 1996-06-06 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
DE19909760B4 (de) 1998-04-17 2015-05-21 Merck Patent Gmbh Benzofuran-Derivate
US7045545B1 (en) * 1999-01-27 2006-05-16 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US6969730B2 (en) * 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
KR100446235B1 (ko) * 2001-05-07 2004-08-30 엘지전자 주식회사 다중 후보를 이용한 움직임 벡터 병합 탐색 방법
WO2003029239A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
CN1561338A (zh) * 2001-10-04 2005-01-05 惠氏公司 作为5－羟基色胺－6配体的苯并二氢吡喃衍生物
US6667322B2 (en) * 2001-10-05 2003-12-23 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole
US20030134835A1 (en) * 2002-01-11 2003-07-17 Arthur Hancock Histamine-3 receptor ligands for diabetes conditions
US7208502B2 (en) * 2002-01-18 2007-04-24 Maniv Energy Capital Methods of treating conditions associated with an Edg-3 receptor
US20030092770A1 (en) * 2002-10-23 2003-05-15 Phil Skolnick Combination therapy for treatment of depression
EP1611902A4 (en) 2003-04-03 2006-04-12 Kyowa Hakko Kogyo Kk MEANS FOR THE PREVENTION AND / OR TREATMENT OF NEUROPATHIC PAIN
US7872014B2 (en) * 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
CA2553084A1 (en) 2004-01-28 2005-08-11 Kissei Pharmaceutical Co., Ltd. Novel benzofuran derivative, medicinal composition containing the same, and uses of these
DE102004030099A1 (de) 2004-06-22 2006-01-12 Grünenthal GmbH Gesättigte und ungesättigte 3-Pyridyl-benzocycloalkylmethyl-amine als Serotonin- und/oder Noradrenalin-Reuptake-Hemmer und/oder µ-Opioidrezeptor-Modulatoren
WO2006000902A1 (en) 2004-06-25 2006-01-05 Pfizer Products Inc. Dihydrobenzofuran compounds and uses thereof
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
EP1879875A1 (en) * 2005-04-22 2008-01-23 Wyeth Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
CA2605435A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AU2006239922A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
CN101389325A (zh) * 2005-04-22 2009-03-18 惠氏公司 药物滥用的治疗
GT200600166A (es) * 2005-04-22 2007-03-14 Derivados de cromano y cromeno y usos de los mismos
AR056321A1 (es) * 2005-04-22 2007-10-03 Wyeth Corp COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
MX2007012936A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
EP1871755A1 (en) * 2005-04-22 2008-01-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
MX2007013023A (es) * 2005-04-22 2007-12-13 Wyeth Corp Tratamiento del dolor.
EP1874292A2 (en) * 2005-04-24 2008-01-09 Wyeth Methods for modulating bladder function
MX2008012212A (es) * 2006-03-24 2008-10-02 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines.

Also Published As

Publication number Publication date
AU2006239918A1 (en) 2006-11-02
PE20061327A1 (es) 2007-01-02
US20080269321A1 (en) 2008-10-30
US20060258715A1 (en) 2006-11-16
CN101198322A (zh) 2008-06-11
EP1871355A1 (en) 2008-01-02
CA2604915A1 (en) 2006-11-02
GT200600163A (es) 2007-03-14
BRPI0610044A2 (pt) 2010-05-25
TW200722081A (en) 2007-06-16
MX2007012882A (es) 2007-12-10
US7396857B2 (en) 2008-07-08
JP2008536946A (ja) 2008-09-11
WO2006116149A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
GT200600518A (es) Derivados de pirimidina
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
CL2008001560A1 (es) Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
PA8591701A1 (es) Derivados de pirrolopirimidina
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY30759A1 (es) Compuestos quimicos
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ECSP088871A (es) Derivados de triazolopirazina
AR047928A1 (es) Derivados de tetrahidropiridoindol
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
UY31141A1 (es) Compuestos de piperidina y sus usos
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias

Legal Events

Date Code Title Description
FA Abandonment or withdrawal